Skip to main content
. 2009 Aug 14;4(8):e6654. doi: 10.1371/journal.pone.0006654

Figure 3. Tumor-free survival curves of CreERT2-p53F/F mice injected with tamoxifen at 3, 6, and 12 months of age.

Figure 3

(A) Kaplan-Meier survival curves are shown for germline p53−/− mice in black (n = 72), CreERT2-p53F/F mice injected with tamoxifen at 3 months in blue (n = 62), at 6 months in green (n = 13), and at 12 months in red (n = 18). (B) Tumor-free survival curves adjusted for time after tamoxifen injection. Line colors represent the same groups as in A. Note that the CreERT2-p53F/F mice injected with tamoxifen at 6 and 12 months of age exhibit a similar median survival as p53−/− mice and a reduced median survival compared to their 3 month injected counterparts. (C) Natural logarithm of mortality rates fitted using the T4253H smoothing algorithm comparing Gompertz variables from CreERT2-p53F/F mice injected with tamoxifen at 3, 6 and 12 months (x-axis in days) show a significantly increased mortality rate in the 12 month injected mice (p = 0.0007). (D) Tumor types observed in CreERT2-p53F/F mice treated with tamoxifen at 3 and 6 months are similar to those observed in germline p53−/− mice. In 12 month injected CreERT2-p53F/F mice, carcinomas show a modest increase and lymphomas a modest decrease.